FOLD · As filed with the SEC
Amicus Therapeutics income statement, by fiscal year
The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Net product sales | 634,210 | 528,295 | 399,356 | 329,233 |
| Cost of goods sold | 72,929 | 52,943 | 37,326 | 38,599 |
| Gross profit | 561,281 | 475,352 | 362,030 | 290,634 |
| Operating expenses: | ||||
| Research and development | 135,843 | 109,362 | 152,381 | 276,677 |
| Selling, general, and administrative | 383,487 | 323,379 | 275,270 | 213,041 |
| Changes in fair value of contingent consideration payable | 0 | 0 | 2,583 | 1,078 |
| Loss on impairment of assets | 1,702 | 0 | 1,134 | 6,616 |
| Restructuring charges | 0 | 9,188 | — | — |
| Depreciation and amortization | 7,460 | 8,547 | 7,873 | 5,342 |
| Total operating expenses | 528,492 | 450,476 | 439,241 | 502,754 |
| Income (loss) from operations | 32,789 | 24,876 | (77,211) | (212,120) |
| Other (expense) income: | ||||
| Interest income | 3,317 | 5,407 | 7,078 | 3,024 |
| Interest expense | — | — | (50,149) | (37,119) |
| Interest expense | (46,159) | (49,598) | — | — |
| Loss on extinguishment of debt | 0 | 0 | (13,933) | 0 |
| Other (expense) income | 10,244 | (9,441) | (15,886) | 4,176 |
| Income (loss) before income tax | 191 | (28,756) | (150,101) | (242,039) |
| Income tax expense | (27,301) | (27,350) | (1,483) | 5,471 |
| Net loss attributable to common stockholders | (27,110) | (56,106) | (151,584) | (236,568) |
| Net loss attributable to common stockholders per common share - basic (in dollars per share) | (0.09) | (0.18) | (0.51) | (0.82) |
| Net loss attributable to common stockholders per common share - diluted (in dollars per share) | (0.09) | (0.18) | (0.51) | (0.82) |
| Weighted-average common shares outstanding - basic (in shares) | 308,363,768 | 304,380,502 | 295,164,515 | 289,057,198 |
| Weighted-average common shares outstanding - diluted (in shares) | 308,363,768 | 304,380,502 | 295,164,515 | 289,057,198 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.